Rainbow Gold

Rainbow Gold (HK) Limited is a strategic subsidiary of CSPC Pharmaceutical Group, one of China's largest and most prominent pharmaceutical companies. The entity serves as the primary vehicle for the group's international business development, specifically focusing on the licensing and global development of innovative biologics and oncology assets. Rainbow Gold's portfolio is particularly strong in oncology, featuring advanced antibody-drug conjugates (ADCs) and monoclonal antibodies targeting high-value pathways such as Claudin 18.2 and GPRC5D. The company has gained significant industry recognition through multi-million dollar licensing agreements with Western biotechnology firms like Elevation Oncology and Corbus Pharmaceuticals. By leveraging the extensive R&D infrastructure of its parent company, Rainbow Gold facilitates the transition of early-stage Chinese innovations into the global clinical pipeline. Its activities are central to CSPC's strategy of expanding its footprint in the global innovative drug market.